
ADC Therapeutics SA ADCT
$ 3.29
-2.37%
Annual report 2022
added 12-21-2024
ADC Therapeutics SA Book Value 2011-2026 | ADCT
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value ADC Therapeutics SA
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 88.7 M | 166 M | 336 M | 111 M | 126 M | 249 M | 141 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 336 M | 88.7 M | 174 M |
Quarterly Book Value ADC Therapeutics SA
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 163 M | 166 M | 187 M | 244 M | 298 M | 336 M | - | - | - | 111 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 336 M | 111 M | 215 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
29 M | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 16.88 | -2.43 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | ||
|
Compugen Ltd.
CGEN
|
132 M | $ 2.79 | -8.09 % | $ 261 M | ||
|
Coherus BioSciences
CHRS
|
61 M | $ 1.6 | -2.15 % | $ 187 M | ||
|
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 7.56 | -3.45 % | $ 207 M | ||
|
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
99.6 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
6.55 M | - | -32.59 % | $ 7.61 M | ||
|
Esperion Therapeutics
ESPR
|
-302 M | $ 3.13 | 0.32 % | $ 651 M | ||
|
Exelixis
EXEL
|
2.16 B | $ 50.41 | -1.36 % | $ 13.7 B | ||
|
Fortress Biotech
FBIO
|
62.2 M | $ 2.43 | 5.65 % | $ 67.8 M | ||
|
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
61 M | $ 23.1 | -3.57 % | $ 299 M | ||
|
Fennec Pharmaceuticals
FENC
|
35.5 M | $ 9.76 | 5.63 % | $ 279 M | ||
|
AbCellera Biologics
ABCL
|
967 M | $ 4.09 | -7.05 % | $ 1.22 B | ||
|
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.59 | - | $ 423 M | ||
|
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - | ||
|
BioNTech SE
BNTX
|
19.2 B | $ 89.16 | -3.08 % | $ 21.5 B | ||
|
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | ||
|
Galectin Therapeutics
GALT
|
-126 M | $ 2.22 | -5.74 % | $ 142 M | ||
|
Gilead Sciences
GILD
|
59 B | $ 130.07 | -1.51 % | $ 162 B | ||
|
Genmab A/S
GMAB
|
36.7 B | $ 26.8 | -0.37 % | $ 1.73 B | ||
|
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.41 | -2.25 % | $ 5.61 M | ||
|
Aeterna Zentaris
AEZS
|
3.84 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | ||
|
Grifols, S.A.
GRFS
|
8.61 B | $ 7.74 | -0.64 % | $ 5.26 B | ||
|
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.72 | -1.05 % | $ 32.9 M | ||
|
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | ||
|
Eton Pharmaceuticals
ETON
|
26.2 M | $ 29.69 | -0.92 % | $ 799 M | ||
|
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
189 M | $ 21.51 | -0.3 % | $ 2.74 B | ||
|
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M |